

Chapter 1

Classification and Evolution of Human Rhinoviruses 2

[AU1] Ann C. Palmenberg and James E. Gern 3

Abstract 4

The historical classification of human rhinoviruses (RV) by serotyping has been replaced by a logical system of comparative sequencing. Given that strains must diverge within their capsid sequenced by a reasonable degree (>12–13 % pairwise base identities) before becoming immunologically distinct, the new nomenclature system makes allowances for the addition of new, future types, without compromising historical designations. Currently, three species, the RV-A, RV-B, and RV-C, are recognized. Of these, the RV-C, discovered in 2006, are the most unusual in terms of capsid structure, receptor use, and association with severe disease in children. 5
6
7
8
9
10
11

Key words Rhinovirus, Evolution, Virus taxonomy, Immunology, Drug resistance 12

1 Historical RV Classification 13

The human rhinoviruses currently comprise the RV-A, RV-B, and RV-C species of the *Enterovirus* genus in the *Picornaviridae* family. This classification status was not always the case. For the RV-A and RV-B, several historic clinical panels archived by the American Type Culture Collection were originally combined and indexed into 100 RV types after assessment of antigenic cross-reactivity or serotyping in rabbits. From these data, and from physical characteristics of the virions (e.g., pH lability), it was obvious that the full list of composite isolates easily subdivided into two related species, the *HRV-A* and *HRV-B*. For many years, these units were assigned to their own genus (*human rhinoviruses* or *HRV*) because the disease presentations (common cold) were observably different from other classical enteroviruses, like poliovirus, coxsackie virus, or ECHO (enteric cytopathic human orphan) viruses. Moreover, they were also different from all other original picornavirus genera, the *Aphthoviruses*, *Cardioviruses*, and *Hepatoviruses*. Before 1985, most virus taxonomy systems were weighted heavily towards phenotypic parameters (i.e., virion stability properties or disease etiologies) 14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31



Fig. 1 Genome map of a typical RV shows the protein names and their involvement in capsid formation or replication processes

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

as it was commonly argued (at that time) that medical-based classification made it easier to teach in clinical settings.

In 1984–1985, the first HRV (B14) was sequenced in its entirety in parallel with the virion crystal structure determination [1, 2]. Surprisingly, the B14 genome organization, including the full array of functional genes (Fig. 1), proved nearly identical to that of poliovirus 1, one of the earliest determined picornavirus sequences [3, 4]. Indeed, as more genome sequences followed, the pattern became evermore apparent. The HRV-A and HRV-B, while distinct in their own groupings, were enterovirus-like in all measures of genome comparisons and probably should be considered as species within that genus. The Picornavirus Study Group Subcommittee (SG) eventually made this recommendation to the International Committee on the Taxonomy of Viruses (ICTV), where it was subsequently adopted [5]. The thorough, deep sequence-based classification precedent established by this decision has helped shape taxonomy protocols for all virus families. As part of the *HRV-Enterovirus* reassignments, the term “Human” was dropped from the species names and 99 of the original types became simply known as “Rhinoviruses,” or “RV,” retaining the RV-A and RV-B species letter designations of the previous system. Within this reclassification context, and after further evaluation of genetic, immunogenic, and receptor use (decay-accelerating factor as a receptor) properties, RV-A87 was reassigned to the *Enterovirus D* species (EV-D68) [6].

57

2 Current Classification

58
59
60
61
62
63
64
65
66
67

New RV isolates are now rarely tested for immunogenicity. The current classification scheme is based on overt similarities in genome organization, capsid properties, and primary sequence conservation [7]. Strains are assigned to the RV-A or RV-B if they share greater than 70 % amino acid identity in the P1, 2C, and 3CD regions with other members. Within the respective species, isolates are subdivided into numeric genotypes that respect the historic naming system, but now rely almost entirely on sequence comparisons of the VP1 protein or VP4/VP2. The preferred nomenclature [8] designates the species letter

(A, B, or C), and type number (e.g., A16). Strain designations are unique to each Genbank accession number and rarely indicated unless required for clarity.

Assignment of a new strain to a known genotype generally requires >86–87 % aligned nucleic acid identity in either or both of the key capsid regions. Type assignments are considered tentative until at least the full VP1 sequence is completed and verified [8]. Full-genome sequencing revealed that some historic types were really more closely related than this (e.g., A54 and A98, or A29 and A44), and others such as A8 and A45, defining “clade D,” were in fact so different from all other RV-A; they perhaps warrant eventual designation as another species [9]. Part of the ongoing mission of the Picornavirus Special Group (SG) is to continually sort out such discontinuities and attempt to provide a common code for new isolates and types as they are discovered. For example, in the past few years, six new types have been added to the RV-A (A101–A106) and five new types have been added to the RV-B (B100–B104). Isolates for A8 and A95 have been merged into a single type (A8), as have A54/A98 (to A54), and A29/A44 (to A29). Other types were split (e.g., B52 into B52 plus B104), or their isolates rearranged (e.g., A36 and A89). All these changes now more accurately reflect strain/type commonalities required by the overlying classification scheme.

An excellent recent review on this topic by McIntyre et al. summarizes the current state of the field [8]. Recent taxonomy proposals approved, or under consideration by the Picornavirus SG or by the ICTV, can be publically reviewed at <http://www.ictvonline.org/virusTaxonomy.asp>. Presently, the RV-A have 77 recognized types and the RV-B have 30 types. Type RV-A1 is unique in that it has assigned isolates that are sufficiently different as to warrant special distinction, as A1A and A1B subtypes. If these units are counted separately, it brings the RV-A to 78 types. Because of the recently recommended mergers among several closely related types, a few of the historic type numbers have been dropped from the current system and are no longer used (A44, A87, A95, A98). If a researcher should discover an isolate sufficiently different to warrant consideration as a new type, they should consult the website curated by the Picornavirus SG (<http://www.picornaviridae.com>). Via links on this site, comparative sequences can be submitted (preferably for the full capsid, but for the full VP1 gene at a minimum) for SG consideration. New type numbers are awarded sequentially. New species designations (*see* below for RV-C) require full ICTV approval.

3 Receptor and Drug Groups

The classic panel of 99 original RV-A and RV-B are the canonical agents of the “common cold.” Many are well studied at the structural and clinical levels. All these isolates use either ICAM-1

114 (89 “major” types) or LDLR (10 “minor” types) as their cellular
115 receptors. The molecular nuances of these interactions have been
116 described by many co-crystallization and EM studies. The set of
117 full-genome sequences, including at least one representative of
118 each historic type, was completed in 2009 [10]. From this work,
119 it became clear that the RV-A+B included in the major and
120 minor groups conserve particular surface footprints that explain
121 how and why these isolates use their respective receptors to
122 interact with cells [11].

123 This same virus panel has been subjected to extensive character-
124 izations according to composite strain sensitivities to a slate of
125 potential therapeutics targeting their capsids [8]. The basic strategy
126 is aimed at inhibiting the virus before infection by intercalating
127 drugs into the unique surface “pockets” characteristic of all entero-
128 virus virions. The type-specific sensitivities were found to subdivide,
129 roughly along species lines, into two experimental groups [12]. The
130 structures of 28 virus-drug complexes have been determined to
131 atomic resolution. The Group-1 viruses (all RV-B plus A8, A13,
132 A32, A43, A45, and A54) have long, narrow pockets interior to
133 their VP1 proteins, which accommodate matching long-chain
134 hydrophobic drugs. The Group-2 viruses (all other RV-A) have
135 shorter, wider VP1 hydrophobic pockets, and therefore accept an
136 alternate cohort of drugs. These points are important to any discus-
137 sion of rhinovirus classification because there is frequent semantic
138 confusion when dividing the historic strains into their species (RV-A
139 or RV-B), or their receptor units (major or minor) or their drug
140 Groups (1 or 2). It should be remembered that each term design-
141 ates separate, non-overlapping properties. None of the most
142 recently added RV types (i.e., A101–106 or B100–104) have ever
143 been directly tested for receptor binding or drug sensitivity. Their
144 respective activities, based on sequence comparison alone, *predict*
145 them to be “major” in terms of receptor, but divided between
146 Groups 1–2 (along species lines) for drug reactivity.

147 4 Rhinovirus C

148 In 2006 the discovery of a new RV species surprised the molecular
149 and clinical communities [13]. The RV-C are clearly rhinoviruses,
150 but unlike RV-A+B, they are not readily propagated in typical cell
151 culture systems, including WI-38, WisL, BEAS-2B, A549, and
152 HeLa lines [11]. These isolates are not “new” in terms of evolu-
153 tion, but rather they were physically undetected by all typical char-
154 acterization methods that required cultured virus growth, such as
155 plaque assays [11]. The current 51 recognized RV-C types (as
156 binned by sequence analysis) were instead identified by PCR while
157 fishing through patient samples for other RV. As with the RV-A+B,
158 each RV-C type includes those isolates whose VP1 sequences

exceed 87 % pairwise identity at the nucleotide level [8, 14]. The RV-C have special clinical relevance since it is now recognized that these strains are associated with up to half of infections in young children [11]. They grow readily in both the lower and upper airways and tolerate higher growth temperatures in culture [15]. Moreover, the RV-C use cell receptors that are not common to the RV-A+B [11]. Unfortunately, these receptors are apparently lost whenever primary tissue snippets are transitioned to undifferentiated monolayers. RV-C can be grown in mucosal organ cultures, but this technique requires the availability of primary human donor samples [11]. Parallel work with differentiated sinus or bronchial epithelial cells at air-liquid interface (ALI) is promising [15, 16], but neither technique has yet produced enough virus for extensive biological studies. Instead, RV-C information relies heavily on comparative sequence analysis to maximize data from limited experimental samples.

To this end, a great many RV-C capsid fragments have been sequenced, and for about 32 types there are (nearly) full-length genome data [17]. Common to all known isolates in this species are unusually large relative deletions (indels) in the VP1 capsid protein. The fundamental VP1 protein cores superimpose among all RV, but the loops that connect the internal β -strands of the RV-C VP1 are shorter by ~22 amino acids relative to the RV-A, and ~28 amino acids relative to the RV-B. The composite structural loops containing these elements supply virtually all of the mass to the fivefold virion plateau. Therefore, the physical RV-C capsid structures are predicted to be very different from the RV-A+B over at least 1/3 of the virion surface [17]. The changes profoundly affect the receptor-binding platform, (predicted) type immunogenicity, and capsid-drug reactivity [17, 18].

5 Physical Characteristics

By way of review, all RV have genome organizations and (general) capsid structures similar to those of other *Enteroviruses* (Fig. 1). But unlike isolates in the other species of this genus, which remain viable at pH 3.0, RV particles (RV-A+B+C) are unstable below pH 5–6. The icosametric capsid (~30 nm diameter) has 60 copies each of proteins VP1, VP2, VP3, and VP4, named in order of descending electrophoretic mobility. The protein shell surrounds a densely packed, single-stranded, positive-sense, RNA genome of 7079 (RV-C1) to 7233 (RV-B92) bases, a count which does not include the variable length 3' poly(A) tail. Like poliovirus, the surfaces of RV-A+B+C capsids are dominated by the three largest proteins. VP4 is internal to the structure, centered near the fivefold axis. Around the exterior fivefold plateau, a symmetrical “canyon” provides receptor-binding sites and immunogenic surfaces.

204 All RV-A + B are major (ICAM-1) or minor (LDLR) with regard to
205 their receptor preference [19], but the cellular receptors used by
206 the RV-C are certain to be different [11] and are currently uniden-
207 tified. Bioinformatics predicts that the RV-C deletions in the VP1
208 regions will produce species-specific topologies for the canyon
209 region and the fivefold plateau and the (common?) RV-C receptor
210 is sure to be compatible with these dramatic changes.

211 The RV genomes are messenger sense, encoding the polyprotein
212 reading frame (ORF) and multiple important RNA structural motifs.
213 Adjacent to the 5' cloverleaf, a regulatory feature for translation and
214 replication, each RV encodes a strain-specific pyrimidine-rich tract
215 that may be involved in suppressing innate immunity triggers [10].
216 The type-1 IRES is 3' to this tract and includes a variable-length stem
217 structure pairing the ORF start site (AUG) with an upstream
218 AUG. Unlike poliovirus, intervening sequences between these AUGs
219 are probably not scanned by initiating ribosomes [20]. The picorna-
220 virus VPg uridylation reaction, required for RNA synthesis, is tem-
221 plated by a special structure called the *cre* (*cis*-acting replication
222 element) whose location varies in every species of picornavirus. For
223 the RV-A, the *cre* is in the 2A gene [21]. For the RV-B, the *cre* is in
224 the 2C gene [21]. The RV-C *cre* has been proposed as one of the two
225 sites in the 1B gene [10, 21, 22]. Neither has been confirmed experi-
226 mentally. The short, 3' untranslated sequences (UTR) are highly
227 variable. Invariably, they configure as an inclusive stem motif display-
228 ing at least one bogus termination codon in the terminal loop. This
229 codon may be in-frame or out-of-frame with the authentic ORF stop
230 site, and has been proposed to play a role in the recruitment of trans-
231 lation termination factors [10].

232 6 Genetic Relationships

233 As might be expected from the original RV typing system, a large
234 degree of sequence diversity among the RV manifests as amino
235 acid changes in capsid surface regions mapped as neutralizing
236 immunogenic epitopes (Nims). The high frequency of mutational
237 fixation in these Nims, particularly for VP1, is one of the key rea-
238 sons for the plethora of recognized RV genotypes. Although it is
239 possible to measure and define comparative relationships among
240 any set of extant isolates, it is virtually impossible to retrace the
241 exact lineages that gave rise to them. "Evolutionary" trees created
242 from VP1 data are quite different from those using VP2/4, 3D,
243 3C, the IRES, or other regions of the genome [10]. In part this is
244 because nonstructural genes (except for 2A) fix mutations at more
245 variable rates. But recombination (*see* below) is also frequent within
246 and between strains from different RV species. Few if any of even
247 the most characteristic lineages are known to breed true.
248 At best a representative phylogram (Fig. 2) can illustrate some
249 measure of relationships among the major clades and highlight




Fig. 2 Circle phylogram of relationships for currently recognized genotypes [8] of RV-A, RV-B, and RV-C. The tree was calculated with neighbor-joining methods from aligned, VP1 RNA sequences, and rooted with data from four enteroviruses (EV) of the EV-A, EV-B, and EV-C species, similar to ref. 10. The Major (“M,” ICAM-1) and minor (“m,” LDLR) receptor groups are indicated if determined experimentally. The RV-C receptor is unknown. Bootstrap values (percent of 200 replicates) are indicated at key nodes

those genotypes that are most similar to each other. When parsing 250
 new clinical isolates into their appropriate types, it is always impor- 251
 tant to remember that the larger the sequence that is compared, 252
 the more accurate the putative classification. Deep sequence align- 253
 ments [8] covering ~1,000 VP1 datasets are especially valuable 254
 when discriminating, say, A25/A62, B52/B104, or other very 255
 similar types. As is characteristic of most such trees, no matter how 256
 they are calculated, this current depiction places the RV-A and 257
 RV-C more closely together on the tree than either is to the 258
 RV-B. Moreover, within the RV-A, a distinctive “clade D” (A8/A45) 259
 always branches off on its own from the other genotypes [10, 23]. 260

261
262
263

At present, there are too few isolates within this clade to change the classification (RV-D?), but as the taxonomy system continues to evolve, that idea remains a possibility.

264 **7 Recombination**

265
266
267
268

In addition to the multitude of available VP1 sequences, completion of the full cohort of RV-A+B genome sequences [10] identified extensive evidence for historic recombination which, de facto, created several of the existing genotype clades (Fig. 3). A18, A34, A54,




Fig. 3 Recombinant origins for many RV-A&B were uncovered by full-genome sequencing [10]. Parents (solid boxes) or progeny (two-color boxes) are founders of many extant clades. This illustration is modified from "Field's Virology" (2013), Ch 18, "Rhinoviruses," Wolters Kluwer, publishers

and A24 are independent derivatives of events between A54 and 269
A75, for example. A54 is also a parent of A38 and A60. Similarly, 270
B27, B93, and B97 have common parents in B37 and B42. Some of 271
these viruses are promiscuous (!) and evidently, simultaneous infec- 272
tions must be a common event. Surprisingly though, none of these 273
known recombinants have exchanged capsid regions. The most 274
common trades include the 5' UTR, primarily upstream of the 275
IRES, or less frequently, fragments from P2–P3 regions. More 276
recent, deep RV data from multiple field isolates has confirmed this 277
idea, and now show clearly that the RV-A and RV-C frequently 278
recombine between themselves, and when they do, they usually 279
exchange not the expected capsid Nims, but 5' UTR regions, and 280
(often) their respective 2A protease genes [24, 25]. Comparative 2A 281
work is under way to document why these particular recombinants 282
are apparently favored. Possibly, divergent protease specificities may 283
help these viruses regulate the overall cell response to infection. 284

Acknowledgements

This work was supported by NIH grant U19 AI104317. The 285
authors thank Wolters Kluwer, publishers of Field's Virology 286
(2013), for permission to include certain text and figures from Ch 287
18, "Rhinoviruses" by the same authors. 288
289

References

<p>291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314</p>	<p>1. Stanway G, Hughes PJ, Mountford R et al (1984) The complete nucleotide sequence of a common cold virus: human rhinovirus 14. <i>Nucleic Acids Res</i> 12:7859–7875</p> <p>2. Erickson JW, Frankenberger EA, Rossmann MG et al (1983) Crystallization of a common cold virus, human rhinovirus 14: isomorphism with poliovirus crystals. <i>Proc Natl Acad Sci U S A</i> 80:931–934</p> <p>3. Kitamura N, Semler BL, Rothberg PG et al (1981) Primary structure, gene organization and polypeptide expression of poliovirus RNA. <i>Nature</i> 291:547–553</p> <p>4. Racaniello VR, Baltimore D (1981) Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. <i>Proc Natl Acad Sci U S A</i> 78: 4887–4891</p> <p>5. Carstens EB, Ball LA (2009) Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2008). <i>Arch Virol</i> 154:1181–1188</p> <p>6. Savolainen C, Blomqvist S, Mulders MN et al (2002) Genetic clustering of all 102 human</p>	<p>rhinovirus prototype strains: serotype 87 is 315 close to human enterovirus 70. <i>J Gen Virol</i> 316 83:333–340 317</p> <p>7. Palmenberg AC, Rathe J, Liggett S (2010) 318 Analysis of the complete genome sequences of 319 human rhinovirus. <i>J Allergy Clin Immunol</i> 320 125:1190–1199 321</p> <p>8. McIntyre CL, Knowles NJ, Simmonds P 322 (2013) Proposals for the classification of 323 human rhinovirus species A, B and C into 324 genotypically assigned types. <i>J Gen Virol</i> 94: 325 1791–1806 326</p> <p>9. Rathe JA, Liu X, Tallon LJ et al (2010) Full- 327 genome sequence and analysis of a novel 328 human rhinovirus strain within a divergent 329 HRV-A clade. <i>Arch Virol</i> 155:83–87 330</p> <p>10. Palmenberg AC, Spiro D, Kuzmickas R et al 331 (2009) Sequencing and analysis of all known 332 human rhinovirus genomes reveals structure 333 and evolution. <i>Science</i> 324:55–59 334</p> <p>11. Bochkov YA, Palmenberg AC, Lee W-M et al 335 (2011) Molecular modeling, organ culture and 336 reverse genetics for a newly identified human 337 rhinovirus C. <i>Nat Med</i> 17:627–632 338</p>
--	---	--

- 339 12. Andries K, Dewindt B, Snoeks J et al (1990) 370
 340 Two groups of rhinoviruses revealed by a panel 371
 341 of antiviral compounds present sequence diver- 372
 342 gence and differential pathogenicity. *J Virol* 373
 343 64:1117–1123 374
 344 13. Dominguez SR, Briese T, Palacios G et al 375
 345 (2008) Multiplex MassTag PCR for respiratory 376
 346 pathogens in pediatric nasopharyngeal washes 377
 347 by conventional diagnostic testing shows a 378
 348 high prevalence of viruses belonging to a newly 379
 349 recognized rhinovirus clade. *J Clin Virol* 43: 380
 350 219–222
 351 14. Simmonds P, McIntyre C, Savolainen-Kopra C 381
 352 et al (2010) Proposals for the classification of 382
 353 human rhinovirus species C into genotypically 383
 354 assigned types. *J Gen Virol* 91:2409–2419
 355 15. Ashraf S, Brockman-Schneider R, Bochkov YA 384
 356 et al (2013) Biological characteristics and prop- 385
 357 agation of human rhinovirus-C in differentiated 386
 358 sinus epithelial cells. *Virology* 436:143–149 387
 359 16. Hao W, Bernard K, Patel N et al (2012) Infection 388
 360 and propagation of human rhinovirus C in 389
 361 human airway epithelial cells. *J Virol* 86:24–32 390
 362 17. Basta HA, Sgro J-Y, Palmenberg AC (2013) 391
 363 Modeling of the human rhinovirus C capsid 392
 364 suggests a novel topology with insights on 393
 365 receptor preference and immunogenicity. 394
 366 *Virology* 448:176–184 395
 367 18. Basta HA, Ashraf S, Bochkov YA et al (2013) 396
 368 Modeling of the human rhinovirus C capsid and 397
 369 antiviral drug resistance. *Virology* 448:82–90 398
 19. Vlasak M, Roivainen M, Reithmayer M et al 399
 (2005) The minor receptor group of human 400
 rhinovirus (HRV) includes HRV23 and
 HRV25, but the presence of a lysine in the VP1
 H1 loop is not sufficient for receptor binding.
J Virol 79:7389–7395
 20. Jackson RJ (1996) Initiation site selection 376
 mechanisms. In: Hershey JWB, Mathews MB,
 Sonenberg N (eds) *Translational control*. Cold
 Spring Harbor Laboratory Press, New York,
 NY, pp 71–112
 21. Steil BP, Barton DJ (2009) Cis-active RNA 381
 elements (CREs) and picornavirus RNA repli- 382
 cation. *Virus Res* 139:240–252 383
 22. Cordey S, Gerlach D, Junier T et al (2008) The 384
 cis-acting replication elements define human 385
 enterovirus and rhinovirus species. *RNA* 14:
 1568–1578 386
 23. Ledford RM, Patel NR, Demenczuk TM et al 387
 (2004) VP1 sequencing of all human rhinovi- 388
 rus serotypes: insights into genus phylogeny 389
 and susceptibility to antiviral capsid-binding 390
 compounds. *J Virol* 78:3663–3674 391
 24. Huang T, Wang W, Bessaud M et al (2009) 392
 Evidence of recombination and genetic diver- 393
 sity in human rhinoviruses in children with 394
 acute respiratory infection. *PLoS One* 4:e6355 395
 25. McIntyre CL, McWilliam Leitch EC, Savolainen- 396
 Kopra C et al (2010) Analysis of genetic diversity 397
 and sites of recombination in human rhinovirus 398
 species C. *J Virol* 84:10297–10310 399
 400